In-vitro diagnostics and laboratory services company Renalytix plc (NASDAQ:RNLX) (LSE:RENX) announced on Friday Medicare's final coverage determination for its kidney disease test, kidneyintelX.dkd.

The test is approved for patients with type 2 diabetes and early-stage chronic kidney disease, with coverage starting 1 August 2024. The established Medicare price for kidneyintelX.dkd is USD950 per test.

This decision follows FDA authorisation, clinical data, guideline inclusion and broad insurance coverage, paving the way for wider test adoption.